HAVCR1 and Hyperglycemia: Tofogliflozin may prevent glomerular (enlarged mesangial area, foot process effacement, podocyte loss) and tubulointerstitial damage (increased expression of MCP‐1 and KIM‐1), partly by ameliorating hyperglycemia, renal inflammation, and abnormal mitochondrial morphology.